Skip to main content
Premium Trial:

Request an Annual Quote

Link Technologies Inks License for PNA's PNA Synthesis Tech

NEW YORK (GenomeWeb News) - Link Technologies has entered a non-exclusive license agreement with PNA Inventor Group that will allow it to manufacture and sell monomers for peptide nucleic acid synthesis worldwide.
Link Technologies said that numerous uses for PNAs have been identified or proposed for molecular biology applications, diagnostic assays, and antisense therapies.
The company added that it expects PNA-related technologies to account for 10 percent of the global DNA synthesis market by 2010. This market is currently worth $800 million and growing at more than 10 percent per year, the company said.
PNAs are oligonucleotide analogs in which the sugar-phosphate backbone of DNA is substituted by a pseudo-peptide backbone. They hybridize to complementary DNA or RNA, but are not degraded by nucleases or proteases, Link Technologies said.
Link Technologies said that it will begin offering PNA monomers that are compatible with commercial automated oligonucleotide, peptide, or combinatorial synthesizers, in July.
Financial terms of the agreement were not released.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.